Evaluation of the New Medicine Service
ISRCTN | ISRCTN23560818 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN23560818 |
ClinicalTrials.gov number | NCT01635361 |
Secondary identifying numbers | 12494 |
- Submission date
- 05/07/2012
- Registration date
- 05/07/2012
- Last edited
- 27/10/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Matthew Boyd
Scientific
Scientific
School of Pharmacy
University Park
Nottingham
NG7 2RD
United Kingdom
Phone | +44 (0)115 9515061 |
---|---|
matthew.boyd@nottingham.ac.uk |
Study information
Study design | Randomised interventional trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | GP practice |
Study type | Quality of life |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | Understanding and appraising the New Medicine Service in the NHS in England |
Study objectives | About 25% medicines prescribed for longterm conditions are not taken as directed, and approximately 15% people receiving a new medicine take few, if any, doses. The New Medicines Service (NMS) is a community pharmacy service that started in England in October 2011 which involves the pharmacist providing additional support to patients starting a new medicine for some breathing problems (asthma & chronic obstructive pulmonary disease [COPD]), high blood pressure, adult onset diabetes or medicines which reduce blood clotting. It aims to improve the way patients take their medicines improving outcomes and reducing costs to the NHS. |
Ethics approval(s) | First MREC, 02/05/2012 ref: 12/WM/0096 |
Health condition(s) or problem(s) studied | All diseases |
Intervention | The effectiveness and cost effectiveness of the NMS will be assessed using a research study where some people will receive the NMS, and some wont, in order to look at the effect of the NMS on problems with their medicines, medicines taking and use of the NHS in general. Data will be collected in the East Midlands, South Yorkshire and London areas. 500 patients will be recruited from a range of different pharmacies and follow them up at 6, 10 and 26 weeks after starting their new medicine to assess effects on medicines taking behaviour, patients reported problems with medicines, referrals to their GP and use of NHS resources. The data gathered will be compared with that being collected routinely by all pharmacies in England to provide wider estimates of cost-effectiveness. The study will also explore how the NMS service is being implemented by pharmacies. A sample of patients from the main study will be followed in more detail. This will involve recording the consultations with the pharmacist and also interviewing patients about their experience of the service. The patients GPs will be interviewed to investigate their views of the service. The trialists will also try to understand why people decline the invitation for the NMS. Follow Up Length: 6 months. |
Intervention type | Other |
Primary outcome measure | Medicines adherence measured at 6, 10 and 26 weeks |
Secondary outcome measures | 1. Cost effectiveness measured at 6 months 2. Operation of the NMS measured 1 year from first recruited patient 3. Patients understanding of their medicines measured at 10 weeks 4. Pharmacovigilance measured 1 year from first recruited patient 5. Professional relationships measured 1 year from first recruited patient 6. Stakeholder experience measured 1 year from first recruited patient |
Overall study start date | 16/07/2012 |
Completion date | 28/02/2014 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | UK Sample Size: 500; Description: The study requires 200 patients in each arm. The sample is calculated to allow for an attrition rate of 20% |
Key inclusion criteria | 1. They are community dwelling patients eligible for NMS (i.e. aged from 14 years starting a new medicine for asthma/COPD, diabetes (Type 2), antiplatelets/anticoagulants or hypertension). 2. There is no upper age limit for providing the NMS hence there is no upper limit for patients taking part in the trial 3. They are able to understand patient/participant study documents 4. They are able and willing to provide informed assent/consent 5. The pharmacist will provide the patient with details of the study to in order to allow the patient to make an informed decision to take part into the study or not 6. Male and female participants |
Key exclusion criteria | 1. Younger patients who may not be able to understand the NMS service and/ or consenting procedure 2. Patients collecting a repeat prescription for a medicine for asthma/COPD, type 2 diabetes mellitus (T2DM), antiplatelets/anticoagulants or hypertension 3. Patients collecting a medicine where the only change from the previous medicine involves a dosage or formulation change only 4. Participants who are unable to understand patient/participant study documents 5. Participants who are unable and unwilling to provide assent/consent |
Date of first enrolment | 16/07/2012 |
Date of final enrolment | 28/02/2014 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University of Nottingham
Nottingham
NG7 2RD
United Kingdom
NG7 2RD
United Kingdom
Sponsor information
University of Nottingham (UK)
University/education
University/education
School of Pharmacy
University Park
Nottingham
NG7 2RD
England
United Kingdom
Website | http://www.nottingham.ac.uk/ |
---|---|
https://ror.org/01ee9ar58 |
Funders
Funder type
Government
National Institute for Health Research (NIHR) - Central Commissioning Facility (UK)
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | Not provided at time of registration |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Protocol article | protocol | 01/12/2013 | Yes | No | |
Results article | 10-week follow-up | 01/10/2016 | Yes | No | |
Results article | cost effectiveness results | 01/12/2017 | Yes | No | |
Results article | 26-week follow-up | 15/11/2019 | 27/10/2022 | Yes | No |
Editorial Notes
27/10/2022: Publication reference added.
09/08/2017: Publication reference added.
10/04/2013: The overall trial end date was changed from 31/03/2013 to 28/02/2014